BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Second- or third-generation TKIs that are approved for treating CML such as dasatinib, nilotinib and ponatinib have also been examined as treatment for GIST, but the targets of those TKIs focus on BCR-ABL and its related mutations, specific targets of CML, and the patient responses in clinical trials have been modest [27,28].